A 41-year-old female diagnosed with multiple sclerosis began ocrelizumab treatment. She received her first treatment course without significant complication. After receiving the first maintenance dose 6 months later, she developed weakness, myalgias, gastrointestinal symptoms, headache, and intermittent fever persisting for 4 weeks. A working diagnosis of serum sickness was determined after excluding other probable entities. She received 3 days of 1 g methylprednisolone intravenously and five plasma exchanges, experiencing gradual improvement. Serum sickness has occurred with monoclonal antibodies including rituximab. This case of possible ocrelizumab-associated serum sickness suggests that clinicians should remain vigilant about this possibility with this medication.

中文翻译：

---

ocrelizumab 输注后可能出现的血清病病例

一名被诊断患有多发性硬化症的 41 岁女性开始接受 ocrelizumab 治疗。她接受了她的第一个疗程，没有出现明显的并发症。6 个月后接受第一次维持剂量后，她出现虚弱、肌痛、胃肠道症状、头痛和持续 4 周的间歇性发热。在排除其他可能的实体后，确定了血清病的有效诊断。她接受了 3 天的 1 g 甲基强的松龙静脉注射和 5 次血浆置换，逐渐好转。使用包括利妥昔单抗在内的单克隆抗体会出现血清病。这起可能与 ocrelizumab 相关的血清病的病例表明，临床医生应该对这种药物的这种可能性保持警惕。